Risk Factors Update Summary
- Risks added regarding investment in Tisento, liquidity uncertainty, and potential equity interest value. This change might result in increased investor caution.
- Risk of inadvertently being deemed an investment company under the Investment Company Act due to asset composition.
- Increased focus on cybersecurity risks, including cyberattacks and data breaches, with potential severe disruptions. This change highlights the importance of data security.
- Potential material adverse effects on operations and financial condition if deemed an investment company.
- Risk of limitations on NOL carryforwards and tax attributes due to ownership changes.
- Addition of risks related to the development of CNS drug therapies, emphasizing challenges and uncertainties. This change underscores the complexity of CNS drug development.
- Uncertainties in tax laws could significantly affect tax obligations, effective tax rate, and financials.
- Limitations on using federal net operating losses (NOLs) and tax attributes to offset future taxable income.
- Impact of Tax Cuts and Jobs Act of 2017 on deducting research and development expenses.
- Risk associated with maintaining cash balances exceeding federally insured limits at financial institutions.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1755237&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.